Mostrar el registro sencillo del ítem
dc.contributor.author
Boccia, Mariano Martín
dc.contributor.author
Baratti, Carlos Maria
dc.date.available
2018-03-16T22:37:59Z
dc.date.issued
2000-12
dc.identifier.citation
Boccia, Mariano Martín; Baratti, Carlos Maria; Involvement of central cholinergic mechanisms in the effects of oxytocin and an oxytocin receptor antagonist on retention performance in mice; Academic Press Inc Elsevier Science; Neurobiology of Learning and Memory; 74; 3; 12-2000; 217-228
dc.identifier.issn
1074-7427
dc.identifier.uri
http://hdl.handle.net/11336/39144
dc.description.abstract
Oxytocin (OT, 0.10 μg/kg, sc) impaired retention of a one-trial step-through inhibitory avoidance task when injected into male Swiss mice 10 min after training, as indicated by retention performance 48 h later. In contrast, the immediate post-training administration of the putative oxytocin receptor antagonist d(CH2)5[Tyr(Me)2, Thr4, Thy-NH2/9] OVT (AOT, 0.30/μg/kg, sc) significantly enhanced retention performance. Neither OT nor AOT affected response latencies in mice not given footshock on the training trial, and neither the impairing effects of OT nor the enhancing effects of AOT were seen when the training-treatment interval was 180 min, suggesting that both treatments influenced memory storage. The effects of OT (0.10 μg/kg, sc) on retention were prevented by AOT (0.03 μg/kg, sc) given immediately after training, but 10 min prior to OT treatment. The central acting anticholinesterase physostigmine (35, 70, or 150 μg/kg, ip), but not its quaternary analogue neostigmine (150 μg/kg, ip), reversed the impairment of retention performance induced by OT, whereas low subeffective doses of the centrally active muscarinic cholinergic antagonist atropine (0.5 mg/kg, ip) or the central acting nicotinic cholinergic antagonist mecamylamine (5 mg/kg, ip), but not methylatropine (0.5 mg/kg, ip) or hexamethonium (5 mg/kg, ip), prevented the enhancement of retention performance caused by AOT. We suggest that oxytocin negatively modulates the activity of central cholinergic mechanisms during the posttraining period that follows an aversively motivated learning experience, leading to an impairment of retention performance of the inhibitory avoidance response. (C) 2000 Academic Press.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Academic Press Inc Elsevier Science
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Acetylcholine
dc.subject
Oxytocin
dc.subject
Oxytocin Antagonists-Memory
dc.subject
Oxytocin Receptors-Memory
dc.subject.classification
Inmunología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Involvement of central cholinergic mechanisms in the effects of oxytocin and an oxytocin receptor antagonist on retention performance in mice
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-03-16T15:12:36Z
dc.journal.volume
74
dc.journal.number
3
dc.journal.pagination
217-228
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Boccia, Mariano Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Baratti, Carlos Maria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentina
dc.journal.title
Neurobiology of Learning and Memory
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1074742799939540
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1006/nlme.1999.3954
Archivos asociados